Pancreatic Cancer Research

ResearcherMie UniversityActive in the last 2 years

Shuji Isaji

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7868-4498; OpenAlex author ID A5060592514. Sources: OpenAlex.

Their work

Papers
31 (first author 4, last author 15)
Trials
0
Grants
0
Labs led
1
Collaborators
95
Papers, trials and grants by year

2012: 2 papers · 2013: none · 2014: 1 paper · 2015: 4 papers · 2016: 1 paper · 2017: 2 papers · 2018: 3 papers · 2019: 6 papers · 2020: 1 paper · 2021: 4 papers · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 31

  1. Aso Visual Abstract: Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18555-4↗
  2. Usefulness and Prognostic Impact of Preoperative Dynamic CT in the Diagnosis of Extrapancreatic Extension in Resectable Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers18111780↗
  3. Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-17988-1↗
  4. Extrapancreatic extension is a better adverse prognostic factor than tumor size in patients with localized pancreatic ductal adenocarcinoma treated with chemor… Co-author DOI 10.1016/j.hpb.2023.06.015↗
  5. New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). Co-author DOI 10.1002/jhbp.1049↗
  6. Role of Serum Carcinoma Embryonic Antigen (CEA) Level in Localized Pancreatic Adenocarcinoma: CEA Level Before Operation is a Significant Prognostic Indicator … Co-author DOI 10.1097/sla.0000000000004148↗
  7. Involvement of superior mesenteric vein and superior mesenteric artery is adverse prognostic factors in patients with localized pancreatic ductal adenocarcinom… Co-author DOI 10.21203/rs.3.rs-2229927/v1↗
  8. Clinical significance and predictors of complete or near-complete histological response to preoperative chemoradiotherapy in patients with localized pancreatic… Last author DOI 10.1016/j.pan.2021.08.011↗
  9. Phase I Study of Preoperative Chemoradiotherapy Using Gemcitabine Plus Nab-Paclitaxel for Patients Who Have Localized Pancreatic Ductal Adenocarcinoma With Con… Co-author DOI 10.1097/mpa.0000000000001902↗
  10. Left-sided Portal Hypertension After Pancreaticoduodenectomy With Resection of the Portal Vein/Superior Mesenteric Vein Confluence in Patients With Pancreatic … Last author DOI 10.1097/sla.0000000000003487↗
  11. Improving the Prognosis of Pancreatic Cancer Through Early Detection: Protocol for a Prospective Observational Study. First author DOI 10.2196/26898↗
  12. International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international … Co-author DOI 10.1016/j.pan.2020.05.011↗
  13. The clinical impact of portal venous patency ratio on prognosis of patients with pancreatic ductal adenocarcinoma undergoing pancreatectomy with combined resec… Last author DOI 10.1016/j.pan.2019.01.020↗
  14. Comparative Study Between Gemcitabine-Based and Gemcitabine Plus S1-Based Preoperative Chemoradiotherapy for Localized Pancreatic Ductal Adenocarcinoma, With S… Last author DOI 10.1097/mpa.0000000000001227↗
  15. Clinical Significance of Plasma Apolipoprotein-AII Isoforms as a Marker of Pancreatic Exocrine Disorder for Patients with Pancreatic Adenocarcinoma Undergoing … Last author DOI 10.1155/2019/5738614↗
  16. Needle tract seeding following endoscopic ultrasound-guided fine-needle aspiration for pancreatic cancer: a report of two cases. Last author DOI 10.1186/s12957-019-1681-x↗
  17. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializi… Co-author DOI 10.1245/s10434-018-07131-8↗
  18. Prognostic Nutritional Index After Chemoradiotherapy Was the Strongest Prognostic Predictor Among Biological and Conditional Factors in Localized Pancreatic Du… Last author DOI 10.3390/cancers11040514↗
  19. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Co-author DOI 10.1016/j.pan.2017.11.011↗
  20. Clinical Significance of Histological Effect and Intratumor Stromal Expression of Tenascin-C in Resected Specimens After Chemoradiotherapy for Initially Locall… Last author DOI 10.1097/mpa.0000000000001022↗
  21. Survival Analysis in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Chemoradiotherapy Followed by Surgery According to the International Consensus o… First author DOI 10.3390/cancers10030065↗
  22. Revised 7th edition of the General Rules for the Study of Pancreatic Cancer by Japan Pancreas Society -revised concepts and updated points. Co-author DOI 10.11405/nisshoshi.114.617↗
  23. [I. The Efficacy of Preoperative Adjuvant Treatment for Pancreatic Ductal Adenocarcinoma Based on the Resectability Criteria according to JPS 7th]. Last author PMID 29066676↗
  24. Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Cli… Last author DOI 10.1097/mpa.0000000000000597↗
  25. Spontaneous Rupture of an Intrasplenic Aneurysm After Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.jemermed.2014.11.025↗
  26. [Epidemiology of pancreatic ductal adenocarcinoma]. Last author PMID 25856992↗
  27. [Open surgical resection for pancreatic cancer]. First author PMID 25857000↗
  28. [Borderline resectable pancreatic ductal adenocarcinoma]. First author PMID 25857062↗
  29. Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of th… Last author DOI 10.1097/mpa.0000000000000059↗
  30. Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoper… Last author DOI 10.1007/s00534-011-0440-3↗
  31. Impact of histological response after neoadjuvant chemoradiotherapy on recurrence-free survival in UICC-T3 pancreatic adenocarcinoma but not in UICC-T4. Last author DOI 10.1097/mpa.0b013e3182236442↗

Closest collaborators

The 25 strongest of 95 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masashi Kishiwada · 20 shared papers, 2012–2023 · strength 1.69
  2. Shugo Mizuno · 19 shared papers, 2012–2023 · strength 1.60
  3. Yasuhiro Murata · 17 shared papers, 2012–2023 · strength 1.43
  4. Aoi Hayasaki · 14 shared papers, 2017–2023 · strength 1.36
  5. Naohisa Kuriyama · 13 shared papers, 2015–2023 · strength 1.20
  6. Hiroyuki Sakurai · 13 shared papers, 2012–2022 · strength 0.96
  7. Hiroyuki Kato · 9 shared papers, 2017–2022 · strength 0.80
  8. Sohei Satoi · 5 shared papers, 2019–2026 · strength 0.76
  9. Yoshiaki Murakami · 4 shared papers, 2019–2026 · strength 0.65
  10. Masayuki Sho · 4 shared papers, 2019–2026 · strength 0.65
  11. Hiroki Yamaue · 4 shared papers, 2019–2026 · strength 0.65
  12. Kazuyuki Gyoten · 5 shared papers, 2021–2023 · strength 0.64
  13. Itaru Endo · 4 shared papers, 2019–2026 · strength 0.63
  14. Yoshinori Azumi · 7 shared papers, 2015–2019 · strength 0.57
  15. Michiaki Unno · 3 shared papers, 2019–2026 · strength 0.52
  16. Toru Shinkai · 4 shared papers, 2017–2023 · strength 0.48
  17. Suguru Yamada · 2 shared papers, 2025–2026 · strength 0.44
  18. Masanori Oshi · 2 shared papers, 2025–2026 · strength 0.44
  19. Takashi Murakami · 2 shared papers, 2025–2026 · strength 0.44
  20. Yasuhiro Yabushita · 2 shared papers, 2025–2026 · strength 0.44
  21. Satoshi Hirano · 2 shared papers, 2025–2026 · strength 0.44
  22. Goro Honda · 2 shared papers, 2025–2026 · strength 0.44
  23. Masayuki Ohtsuka · 2 shared papers, 2025–2026 · strength 0.44
  24. Takahiro Ito · 3 shared papers, 2018–2023 · strength 0.35
  25. Benson Kaluba · 2 shared papers, 2022–2023 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.